CNClinicalTrials.govClinical trialNot applicableEnrolling by invitation
Plasma Exosome RNA to Diagnose Prostate Cancer
Official record
- Identifier
NCT06604130- Recruiting locations
country
China- Interventions studied
- Prostate cancer screening decision
- Lead sponsor
- Xijing Hospital
- Target enrolment
- 1600 participants
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Status
- Enrolling by invitation
- First posted
- Sep 19, 2024
- Last updated on the registry
- Jul 30, 2026
- Age
- 18 Years
- Sex
- MALE
- Study contact
- No public contact is listed on the official record.
- Eligibility criteria
Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.
Inclusion Criteria: 1. Blood prostate-specific antigen PSA\>4ng/dl; 2. Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging, and PSMA PET/CT examination. 3. The patient is willing to undergo prostate biopsy. Exclusion Criteria: 1. Previous diagnosis of prostate cancer through prostate biopsy; 2. History of other malignant tumors in the past two years; 3. According to the research physician\'s judgment, serious complications may occur and affect the normal conduct of the experiment
- Indexed under
- Prostate Cancer
This site does not provide medical advice
TrialBeacon only aggregates links to publicly available official information. It does not recommend, rank or evaluate any treatment, trial or medicine, and nothing here implies suitability for any individual. Please discuss anything you find with your treating doctor, and always rely on the original official page — records change over time. Full disclaimer.